# US 8,277,794 B2 · Immune privileged and modulatory progenitor cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,794 B2
- Document ID: US8277794B2
- Status: Granted
- Kind: B2
- Application number: 12/299,736
- Filed: 2007-05-04
- Published: 2009-11-19
- Granted: 2012-10-02
- Earliest claimed: 2006-05-05
- Inventors: John E. Davies; Jane Ennis; Alejandro Gomez-Aristiz-Abal; Dolores Baksh
- Web page: https://patentgrep.com/patent/US8277794B2

## CPC

- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- A61P 17/00: Drugs for dermatological disorders
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 5/0665: {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also employ soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.

## Claims

### Claim 1

A method for treating a subject having or at risk of developing an adverse immune reaction, comprising administering to the subject an immunomodulating effective amount of an agent selected from umbilical cord perivascular cells, wherein said adverse immune reaction is directed against biological material other than said agent and wherein said administering treats said subject by inhibiting or reducing said adverse immune reaction.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has or is at risk for graft versus host disease.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject has or is at risk for a mixed lymphocyte reaction.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject has or is at risk for graft rejection.

### Claim 5 (depends on 4)

The method of claim 4, wherein the graft is a skin graft.

### Claim 6 (depends on 4)

The method of claim 4, wherein the graft is an organ graft.

### Claim 7 (depends on 4)

The method of claim 4, wherein the graft is a marrow graft.

### Claim 8 (depends on 4)

The method of claim 4, wherein the graft is a peripheral blood graft.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject has an autoimmune disorder.

### Claim 10 (depends on 1)

The method of claim 1, wherein the subject is afflicted with a leukemia and is at risk for graft versus host disease.

### Claim 11 (depends on 1)

The method of claim 1, wherein the umbilical cord perivascular cells are human umbilical cord perivascular cells (HUCPVCs).

### Claim 12 (depends on 1)

The method of claim 1, wherein the umbilical cord perivascular cells comprise a transgene that encodes a protein of interest.

### Claim 13 (depends on 11)

The method of claim 11, wherein the HUCPVCs are substantially MHC double negative.

### Claim 14 (depends on 11)

The method of claim 11, wherein the HUCPVCs are present in a unit dose in the range from 0.01 to 5 million HUCPVCs per kilogram of subject.
